Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.

Stein S, Zhao R, Haeno H, Vivanco I, Michor F.

PLoS Comput Biol. 2018 Jan 2;14(1):e1005924. doi: 10.1371/journal.pcbi.1005924. eCollection 2018 Jan.

2.

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.

Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Carro MS, Curiel-GarcĂ­a A, Campos C, Pourmaleki M, Grommes C, Vivanco I, Rohle D, Bielski CM, Taylor BS, Hollmann TJ, Rosenblum M, Tempst P, Blenis J, Squatrito M, Mellinghoff IK.

Nat Commun. 2017 Dec 11;8(1):2035. doi: 10.1038/s41467-017-02185-w.

3.

IQGAP1 controls tight junction formation through differential regulation of claudin recruitment.

Tanos BE, Perez Bay AE, Salvarezza S, Vivanco I, Mellinghoff I, Osman M, Sacks DB, Rodriguez-Boulan E.

J Cell Sci. 2015 Mar 1;128(5):853-62. doi: 10.1242/jcs.118703. Epub 2015 Jan 14.

4.

A kinase-independent function of AKT promotes cancer cell survival.

Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C, Mellinghoff IK.

Elife. 2014 Dec 31;3. doi: 10.7554/eLife.03751.

5.

Targeting molecular addictions in cancer.

Vivanco I.

Br J Cancer. 2014 Nov 25;111(11):2033-8. doi: 10.1038/bjc.2014.461. Epub 2014 Sep 30. Review.

6.

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death.

Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG.

Mol Syst Biol. 2012 Jun 26;8:589. doi: 10.1038/msb.2012.20.

7.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

8.

Epidermal growth factor receptor inhibitors in oncology.

Vivanco I, Mellinghoff IK.

Curr Opin Oncol. 2010 Nov;22(6):573-8. doi: 10.1097/CCO.0b013e32833edbdf. Review.

PMID:
20739887
9.

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.

Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6459-64. doi: 10.1073/pnas.0911188107. Epub 2010 Mar 22.

10.

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA.

Nat Genet. 2010 Jan;42(1):77-82. doi: 10.1038/ng.491. Epub 2009 Nov 29.

11.

Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency.

Peng L, Wu TT, Tchieu JH, Feng J, Brown HJ, Feng J, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jamieson C, Sun R.

J Gen Virol. 2010 Feb;91(Pt 2):463-9. doi: 10.1099/vir.0.015073-0. Epub 2009 Oct 28.

12.

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W.

J Clin Invest. 2009 Oct;119(10):3000-10. doi: 10.1172/JCI38746. Epub 2009 Sep 14.

13.

14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition.

Meng S, Arbit T, Veeriah S, Mellinghoff IK, Fang F, Vivanco I, Rohle D, Chan TA.

Cell Cycle. 2009 Jul 15;8(14):2238-46. Epub 2009 Jul 12.

PMID:
19502805
14.

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40. doi: 10.1073/pnas.0900571106. Epub 2009 May 28.

15.

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. Epub 2007 Dec 6.

16.

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.

Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H.

Cancer Res. 2007 Jul 1;67(13):6083-91.

17.

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.

Cancer Cell. 2007 Jun;11(6):555-69.

18.

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.

PLoS Med. 2006 Dec;3(12):e485.

19.

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.

20.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

21.

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL.

Cancer Cell. 2004 Nov;6(5):517-27.

22.

Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene.

Jain A, Lam A, Vivanco I, Carey MF, Reiter RE.

Mol Endocrinol. 2002 Oct;16(10):2323-37.

PMID:
12351697
23.

The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Vivanco I, Sawyers CL.

Nat Rev Cancer. 2002 Jul;2(7):489-501. Review. No abstract available.

PMID:
12094235
24.

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A.

Cancer Res. 2001 Feb 15;61(4):1686-92.

25.

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE.

Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8.

Supplemental Content

Loading ...
Support Center